U.S. Markets closed

Tetra Bio-Pharma Inc. (TBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.1850-0.0050 (-2.63%)
At close: 3:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1800
Open0.1800
Bid0.1850 x N/A
Ask0.1900 x N/A
Day's Range0.1750 - 0.1900
52 Week Range0.1350 - 0.3700
Volume1,335,404
Avg. Volume2,337,236
Market Cap68.109M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
    ACCESSWIRE

    Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis

    * Tetra strengthens its intellectual property portfolio * Approximately 12% of women may have early symptoms of Interstitial CystitisOTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark Office for patent application number 16/190,450.

  • Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada
    ACCESSWIRE

    Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada

    * REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug * The addressable market is estimated to be $80M CDN by 2022OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules New Drug Submission (NDS) file by responding to a request for more information from Health Canada, as previously announced on March 15, 2021.

  • FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients
    ACCESSWIRE

    FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients

    * FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDSOTTAWA, ON / ACCESSWIRE / April 5, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that the U.